Kwality Pharmaceuticals Ltd has presented details of its drug development pipeline and product portfolio as part of its investor presentation, covering biosimilar candidates, monoclonal antibodies, and a hormone product pipeline at varying stages of development.

Biosimilar and Monoclonal Antibody Pipeline

The company has outlined four key molecules under development, spanning biosimilars and monoclonal antibodies, with target launch timelines set between H2 CY27 and H1 CY28. The pipeline reflects a range of development stages, from early-stage research to clinical trials and proof-of-concept achievements. The following table summarises the current status of each molecule:

Erythropoietin (EPO), the company's biosimilar candidate, is the most advanced in the pipeline, currently undergoing clinical trials with a target launch in H2 CY27. Pembrolizumab, a monoclonal antibody, has achieved proof of concept and is also targeting H2 CY27. Nivolumab and Pertuzumab are at earlier stages—early development and research phase respectively—with Pertuzumab targeting a slightly later launch in H1 CY28.

Hormone Product Portfolio

Beyond its biosimilar and monoclonal antibody pipeline, Kwality Pharmaceuticals has also outlined a hormone product portfolio covering sex hormones and synthetic hormones, as well as products requiring bioequivalence (BE) studies. The portfolio spans both injectable and oral solid dosage (OSD) forms, with development at various stages of initiation and shortlisting.

The sex hormones category has more than 20 products shortlisted in injectable form, with development already initiated. The synthetic hormones segment similarly has more than 20 products shortlisted across OSD and injectable forms, with shortlisting complete. Additionally, more than 10 products requiring BE studies in OSD form have been queued in the pipeline.

Company Overview

Kwality Pharmaceuticals Ltd is headquartered at 6th Milestone, Majitha Road, Amritsar-143601, Punjab, India. Investor relations for the company are managed by Go India Advisors.

Kwalitity Pharmaceuticals Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with BSE Limited on April 08, 2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates that companies confirm the proper handling of securities received for dematerialization during each quarter.

Certificate Details

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 06, 2026. The certificate confirms that all securities received from depository participants for dematerialization up to March 31, 2026 were properly confirmed to the depositories.

The registrar verified that:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities are listed on stock exchanges where previously issued securities are traded
• Security certificates were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Corporate Compliance

Gurpreet Kaur, Company Secretary and Compliance Officer, submitted the certificate to BSE Limited's Department of Corporate Services. The submission ensures the company maintains its compliance status with SEBI's depositories and participants regulations.

This quarterly filing represents part of the company's ongoing regulatory compliance obligations, ensuring transparency in share dematerialization processes and maintaining good standing with market regulators and stock exchanges.